Prescription non-stimulant medication approved for ADHD in children, adolescents, and adults. A selective norepinephrine reuptake inhibitor (NRI) that provides 24-hour symptom coverage without abuse potential. Particularly suitable for patients with comorbid anxiety, substance use disorders, or those who cannot tolerate stimulants. Takes 4–6 weeks for full therapeutic effect. Dosage must be determined by your prescribing physician.
Evidence rating strong. Most-documented uses: adhd symptom improvement, no abuse or dependence potential, 24-hour symptom coverage. 10 sources indexed (2013–2025), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Selectively inhibits the presynaptic norepinephrine transporter (NET) in the prefrontal cortex. Since dopamine reuptake in the prefrontal cortex is primarily mediated by NET (rather than DAT), atomoxetine also increases prefrontal dopamine levels. Does not significantly affect dopamine in the nucleus accumbens, accounting for its lack of abuse potential.
Class
Non-Stimulant ADHD Medication
Dosing
Dosing & protocol.
Common range
0.5–1.4 mg/kg/day in children; 40–100 mg daily in adults (as prescribed by your physician)
Recommended form
Capsule
Can be taken with or without food. May be taken once daily in the morning or divided into morning and late afternoon doses. Do not open capsules.8
Atomoxetine and cocaine both increase noradrenergic cardiovascular stress. A monitored inpatient study in cocaine-experienced participants found atomoxetine plus intravenous cocaine was tolerated at tested doses, but cocaine still produced heart-rate and blood-pressure responses; a later abstinent-user study found atomoxetine increased heart rate and systolic blood pressure versus placebo. Real-world cocaine dose, route, adulterants, and redosing make co-use unsafe outside monitored research conditions.
Recommendation: Avoid cocaine while taking atomoxetine. Do not take extra atomoxetine to offset cocaine crash, fatigue, or attention problems. Seek emergency care for chest pain, severe headache, fainting, severe agitation, shortness of breath, or a fast or irregular heartbeat.
Atomoxetine exposure is highly sensitive to CYP2D6 inhibition. A clinical pharmacokinetic study showed potent CYP2D6 inhibition with paroxetine markedly increased atomoxetine exposure. Berberine has human clinical evidence of CYP2D6 inhibition after repeated dosing, so berberine could raise atomoxetine exposure even though the exact atomoxetine-berberine combination has not been directly tested.
Recommendation: Ask your prescriber or pharmacist before starting berberine while taking atomoxetine, especially if you are on a higher atomoxetine dose, have CYP2D6 poor-metabolizer status, or also take CYP2D6 inhibitors. Monitor for new insomnia, appetite loss, dry mouth, palpitations, higher blood pressure, urinary hesitation, or unusual irritability.
di Giacomo E, Confalonieri V, Tofani F et al.. Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis. JAMA network open. 2024
Hennissen L, Bakker MJ, Banaschewski T et al.. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS drugs. 2017
Pringsheim T, Hirsch L, Gardner D et al.. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2015
Messineo L, Preuss M, Azarbarzin A et al.. Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity: A Randomized Crossover Trial. Chest. 2025
Mwesigwa N, Millar Vernetti P, Kirabo A et al.. Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. Clinical autonomic research : official journal of the Clinical Autonomic Research Society. 2024
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Atomoxetine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack